Previous 10 | Next 10 |
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis PR Newswire NEW HAVEN, Conn. , March 8, 2023 /PRNewswire/ -- Trevi T...
Trevi Therapeutics to Participate in Upcoming March Conferences PR Newswire Frazier/Fenwick Winter Investor Event, March 7-10 Oppenheimer 33 rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13 , ...
Trevi Therapeutics to Present and Participate in Upcoming February Conferences PR Newswire BIO CEO & Investor Conference, February 6-9 – Corporate presentation Tuesday, February 7 , at 10:45 a.m. ET SVB Securities Global Biopharma Conference,...
Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough...
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences PR Newswire NEW HAVEN, Conn. , Jan. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Ha...
Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference PR Newswire Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10 , at 3:00 p.m. PT ...
Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer PR Newswire David Clark , MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn. , Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc....
Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham &...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...